N/A
Completed N=56
Sequences of Aerobic and Resistance Exercise and Cardio-metabolic Functions in T2D
Source: ClinicalTrials.gov NCT06145542 ↗Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Fasting Glucose at Baseline — 7.2; 7.0 mmol/L
Summary
Aerobic exercise and resistance exercise are two types of exercise commonly used in physical conditioning. Compared to aerobic exercise, a combination of aerobic and resistance exercise has been linked to a greater reduction in hemoglobin A1c (HbA1c) among patients with type 2 diabetes (T2D). However, it is not clear that in a concurrent aerobic-resistance training session, whether the orders of the two types of exercise could act differently in glucose metabolism. This randomized trial aims to investigate the effect of the sequence of exercise modalities (aerobic-resistance vs resistance-aerobic in a training session) on glycemic control among T2D patients following an 8-wk intervention period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fasting Glucose at Baseline |
7.2; 7.0 | — |
| PRIMARY Fasting Glucose at Follow-up |
7.2; 7.4 | — |
| PRIMARY Hemoglobin A1c (HbA1c) at Baseline |
7.5; 7.3 | — |
| PRIMARY Hemoglobin A1c (HbA1c) at Follow-up |
7.0; 7.2 | — |
| PRIMARY Continuous Glucose Monitoring at Baseline (Mean, sd, Lage) |
8.7; 8.1; 2.2; 2.1; 8.7; 8.3 | — |
| PRIMARY Continuous Glucose Monitoring at Baseline (Coefficient of Variation) |
24.1; 25.1 | — |
| PRIMARY Continuous Glucose Monitoring at Baseline (Tir, Tar, Tbr) |
72.3; 77.4; 33.6; 23.9; 0.4; 0.9 | — |
| PRIMARY Continuous Glucose Monitoring at Follow-up (Mean, sd, Lage) |
8.2; 8.4; 2.4; 2.1; 9.1; 8.1 | — |
| PRIMARY Continuous Glucose Monitoring at Follow-up (Coefficient of Variation) |
26.1; 25.6 | — |
| PRIMARY Continuous Glucose Monitoring at Follow-up (Tir, Tar, Tbr) |
75.9; 78.0; 27.6; 26.1; 1.4; 0.9 | — |
Eligibility Criteria
Inclusion Criteria
- Age 50-70 years;
- Type 2 diabetes diagnosed as: random blood glucose ≥11.1mmol/L (200mg/dL) or fasting blood glucose ≥7.0mmol/L (126mg/L) or oral glucose tolerance test (2h) ≥11.1mmol/L (200mg/dL) or glycated hemoglobin (HbA1c) ≥ 6.5%;
- The course of type 2 diabetes lasted for one year or longer;
- Willing to participate and sign the informed consent form voluntarily
Exclusion Criteria
- Type 1 diabetes;
- Fasting blood glucose (FBG)>16.7mmol/L;
- Severe complications of diabetes such as acute infection, diabetic ketoacidosis, and plantar lesions;
- Severe kidney disease, cardiovascular and cerebrovascular diseases as identified by a specialist;
- Musculoskeletal, neurological, psychiatric or other disorders which limit the ability to exercise as identified by a specialist;
- Doing physical exercise regularly (≥ 3 times per week, at least 1 hour per session of moderate to vigorous activities);
- Currently under dietary program for weight loss;
- Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at rest;
- Abnormal electrocardiogram (rest and exercise);
- Other comorbidities or medications irrelevant to diabetes treatment that may influence glycemia during the past 6 months
Data sourced from ClinicalTrials.gov (NCT06145542). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.